Preparing stock dashboard...
Preparing stock dashboard...
6838.TW - Taiwan - Healthcare - Biotechnology
Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and colorectal cancer. It has a strategic partnership with Eyenovia, Inc. for the development of novel ophthalmic therapeutic; and Singapore Eye Research Institute to develop ophthalmic formulations for corneal diseases. Formosa Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Taipei City, Taiwan.
Data updated June 17, 2026
| Metric | Value ('000,000) |
|---|
Latest period compared with the previous period and the matching prior-year period.
Loading financial changes...
Scores this stock using the same metrics model as the compare page.
| Metric | Value | Score |
|---|
Calculated locally from stored daily price and volume history.
Loading technical analysis...
Mouse wheel or pinch to zoom. Drag chart to pan. Double-click to reset zoom.